Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
The clinical efficacy and durability of KRAS<sup>G12C</sup>-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS<sup>G12C</sup>-targeted therapy and immunotherapy-unifying strategies that utilize covalently modif...
| Príomhchruthaitheoirí: | , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Cell Press
2023
|